Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

Core Insights - Affimed N.V. announced that an abstract on AFM24 dose optimization has been accepted for presentation at the AACR Annual Meeting 2025 [1][2] Group 1: Presentation Details - The title of the poster presentation is "Dose-Optimization Using Exposure Response Analysis in AFM24 (in Monotherapy and with Atezolizumab) in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer" [2] - The presentation will take place on April 29, 2025, from 9:00 AM to 12:00 PM CDT [2] - The published abstract number is CT161, and it will be available online on April 25, 2025 [3] Group 2: About AFM24 - AFM24 is a tetravalent, bispecific ICE® that activates the innate immune system by binding to CD16A on innate immune cells and epidermal growth factor receptors (EGFR) [4] - The mechanism of action for AFM24 involves engaging innate immune cells for tumor cell killing through antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis [4] Group 3: About Affimed N.V. - Affimed is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to fight cancer [5] - The company's innate cell engagers (ICE®) are designed to target and kill a variety of hematologic and solid tumors [5] - Affimed is headquartered in Mannheim, Germany, and is led by a team of biotechnology and pharmaceutical leaders [5]